Ra Capital Management, L.P. Purchases 124,893 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 124,893 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77. Following the completion of the purchase, the director directly owned 16,763,043 shares of the company’s stock, valued at $149,023,452.27. The trade was a 0.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Trading Up 11.6%

Shares of ARTV opened at $9.94 on Thursday. The firm has a market cap of $245.72 million, a PE ratio of -2.81 and a beta of 2.38. The company’s 50 day simple moving average is $9.07 and its 200-day simple moving average is $6.28. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC increased its position in shares of Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after buying an additional 37,053 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the fourth quarter valued at $341,000. Finally, Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter valued at $67,000.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ARTV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wedbush raised their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Artiva Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.